Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.

Endocrinology (2014-12-31)
Cecilia Karlsson, Stephan Hjorth, Martin Karpefors, Göran I Hansson, Björn Carlsson
RESUMEN

The individual weight loss response to obesity treatment is diverse. Here we test the hypothesis that the weight loss response to the CB1 receptor antagonist rimonabant is influenced by endogenous levels of receptor agonists. We show that baseline anandamide levels and body weight independently contribute to predict the treatment response to rimonabant in rodents, demonstrating that addition of biomarkers related to mode of action is relevant for a personalized health care approach to obesity treatment.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
tert-Butyl methyl ether, anhydrous, 99.8%
Sigma-Aldrich
tert-Butyl methyl ether, suitable for HPLC, ≥99.8%
Sigma-Aldrich
tert-Butyl methyl ether, ACS reagent, ≥99.0%
Sigma-Aldrich
tert-Butyl methyl ether, HPLC Plus, for HPLC, GC, and residue analysis, 99.9%
Sigma-Aldrich
2-Methylpentane, ≥99%
Sigma-Aldrich
tert-Butyl methyl ether, reagent grade, ≥98%
Sigma-Aldrich
Palmitoylethanolamide
Sigma-Aldrich
2-Methylpentane, ≥95.0% (GC)
Supelco
tert-Butyl methyl ether, analytical standard
Sigma-Aldrich
tert-Butyl methyl ether, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
Arachidonylethanolamide, ≥97.0% (TLC), oil
Supelco
2-Methylpentane, analytical standard
Supelco
tert-Butyl Methyl Ether, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
tert-Butyl methyl ether, HPLC Plus, for HPLC, GC, and residue analysis, 99.9%
Sigma-Aldrich
N-Oleoylethanolamine, ~98% (TLC)
Sigma-Aldrich
tert-Butyl methyl ether, reagent grade, 98%
Supelco
tert-Butyl methyl ether, suitable for HPLC, ≥99.8% (GC)